Natamycin (Natacyn) - antifungal

Natamycin, marketed under the brand name Natacyn, is a polyene antifungal medication that represents the gold standard for treating fungal keratitis in horses. This ophthalmic suspension is the only commercially available topical antifungal preparation specifically formulated for ocular use, making it an essential medication in equine ophthalmology. Fungal eye infections are significantly more common in horses than in other domestic animals, and natamycin has proven highly effective against the most prevalent fungal organisms affecting equine corneas.

The mechanism of action of natamycin involves binding to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and lead to cell death. Unlike some systemic antifungals, natamycin achieves this effect through direct contact with fungal organisms rather than requiring systemic absorption. This targeted approach makes it particularly well-suited for treating superficial fungal infections of the cornea where direct drug-to-organism contact is achievable through topical application.

Natamycin is available as a 5% ophthalmic suspension that requires shaking before each use to ensure uniform distribution of the active ingredient. The medication has a characteristic milky white appearance due to its suspension formulation. Administration involves instilling drops directly into the affected eye, with frequency determined by the severity of infection and veterinary guidance. The suspension is designed to provide prolonged contact time with the corneal surface, enhancing antifungal activity.

The safety profile of natamycin in horses is generally favorable when used as directed under veterinary supervision. Because the drug has minimal systemic absorption when applied topically to the eye, systemic side effects are rare. However, treatment of fungal keratitis requires commitment to an extended treatment course, often lasting several weeks to months, and close monitoring by an equine ophthalmologist or veterinarian experienced in treating ocular conditions. Premature discontinuation of therapy frequently results in recurrence of infection and potential progression of corneal damage.

The primary indication for natamycin in horses is the treatment of fungal keratitis, also known as keratomycosis. This serious ocular condition occurs when fungal organisms invade the corneal tissue, typically following corneal trauma or in immunocompromised eyes. Horses are uniquely susceptible to fungal keratitis compared to other domestic species, with the condition representing a significant percentage of all equine corneal ulcers, particularly in warm, humid climates and during late summer and fall months when fungal spore counts are highest.

Fungal keratitis in horses is most commonly caused by Aspergillus and Fusarium species, both of which are highly susceptible to natamycin. Aspergillus infections often present with a characteristic feathery or satellite appearance at the ulcer margins, while Fusarium may produce a more aggressive, rapidly progressive infection. Natamycin demonstrates excellent activity against both organisms, making it the first-line topical antifungal choice for equine keratomycosis when these common pathogens are suspected or confirmed through culture and cytology.

Beyond treating active fungal keratitis, natamycin may be used prophylactically in horses with corneal ulcers that are not responding appropriately to antibacterial therapy, as this clinical presentation often suggests underlying fungal involvement. Veterinarians may also initiate natamycin therapy while awaiting culture results in geographic regions or seasons where fungal keratitis prevalence is high. This empirical approach helps prevent progression of infection during the several days required for fungal culture results.

Natamycin is also indicated for treating fungal infections of other ocular structures, including fungal conjunctivitis and blepharitis, though these conditions are less common than corneal involvement. In cases of deep stromal fungal infection or those involving the anterior chamber of the eye, natamycin may be used in combination with systemic antifungal medications to achieve adequate drug concentrations in deeper tissues where topical penetration is limited.

The selection of natamycin over other antifungal agents is based on several factors, including the specific fungal organism involved, the depth and severity of corneal involvement, and the availability of alternative medications. For superficial Aspergillus and Fusarium infections, natamycin typically provides superior efficacy compared to azole antifungals. However, for deeper infections or those caused by yeasts such as Candida species, combination therapy or alternative agents may be preferred based on veterinary ophthalmologist recommendations.

Dosing protocols for natamycin in horses are determined by the treating veterinarian based on the severity and extent of fungal infection, the specific organism involved, and the individual patient's response to therapy. Because fungal keratitis can rapidly progress and threaten vision, intensive initial treatment is typically required. Horse owners should understand that successful treatment demands strict adherence to prescribed dosing schedules, which may initially seem demanding but are essential for resolving infection.

Typical initial treatment protocols for active fungal keratitis involve frequent application of natamycin ophthalmic suspension. During the acute phase, the medication may be prescribed as frequently as every one to two hours around the clock for the first several days to achieve and maintain therapeutic drug concentrations at the corneal surface. This intensive schedule requires significant commitment from horse owners or caretakers but is critical for controlling rapidly dividing fungal organisms before they penetrate deeper into corneal tissue.

As the infection begins to respond to treatment, evidenced by reduced inflammation, decreased stromal infiltrate, and epithelialization of the ulcer bed, the dosing frequency is gradually tapered. This reduction typically progresses from hourly to every two hours, then to every four hours, and eventually to four times daily. The tapering schedule is individualized based on clinical response and should only be adjusted under veterinary guidance. Premature reduction in dosing frequency is a common cause of treatment failure and recurrence.

Proper administration technique is essential for optimal drug delivery. Before each application, the bottle should be shaken vigorously to resuspend the medication, as natamycin tends to settle. The horse should be adequately restrained, and the head positioned to allow drop instillation. The lower eyelid is gently pulled down to create a pocket, and one to two drops are instilled without touching the dropper tip to the eye or surrounding tissues to prevent contamination. Following instillation, brief closure of the eyelids helps distribute the medication across the corneal surface.

Treatment duration for fungal keratitis is substantially longer than for bacterial infections, often extending four to eight weeks or longer depending on infection severity and response. Many cases require six weeks of therapy minimum, and some deep or complicated infections may need treatment for several months. Continuation of treatment for at least one to two weeks after apparent clinical resolution helps ensure complete eradication of fungal organisms and reduces recurrence risk.

If a dose is missed, it should be administered as soon as remembered, then the regular schedule resumed. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped rather than doubling up. Owners should contact their veterinarian if multiple doses are missed, as this may compromise treatment efficacy and require schedule adjustment. Maintaining a written log of administration times helps ensure compliance with complex dosing schedules.

Natamycin is generally well-tolerated in horses when used as directed for ophthalmic application. The most common side effects are local reactions at the site of application, which are typically mild and do not require discontinuation of therapy. Because minimal systemic absorption occurs with topical ocular use, systemic side effects are exceedingly rare. However, owners should monitor their horses during treatment and report any concerning changes to their veterinarian.

Mild local irritation following instillation is the most frequently observed side effect. Horses may exhibit brief discomfort, increased blinking, or mild tearing immediately after application. These reactions typically resolve within minutes and do not indicate a need to discontinue treatment. The suspension formulation may temporarily cause mild blurring of vision due to the opaque nature of the medication, but this clears as the drug distributes across the ocular surface.

Some horses may develop hypersensitivity reactions to natamycin or the inactive ingredients in the formulation. Signs of allergic reaction may include increased redness, swelling of the eyelids, persistent tearing, or worsening of ocular discharge. These reactions are uncommon but warrant veterinary evaluation to determine whether treatment should be modified or an alternative antifungal substituted. True allergic reactions to natamycin are rare but have been documented.

Serious adverse effects from natamycin ophthalmic use are unusual. However, any sudden worsening of the eye condition, development of severe pain, significant increase in corneal cloudiness, or changes suggesting deeper infection should prompt immediate veterinary evaluation. These signs may indicate treatment failure, development of resistance, or progression of infection rather than drug side effects per se, but distinguishing between these possibilities requires professional assessment.

Long-term use of natamycin, which is often necessary for fungal keratitis, has not been associated with significant cumulative toxicity to ocular tissues. The medication does not appear to impair corneal healing when used appropriately, though some practitioners prefer to reduce frequency once epithelialization is complete. Chronic use over many months is occasionally necessary for persistent infections, and such extended therapy is generally well-tolerated under veterinary monitoring.

The primary contraindication for natamycin use is known hypersensitivity to the medication or any component of the formulation. Horses that have previously experienced allergic reactions to natamycin should not receive the drug, and alternative antifungal therapy should be selected. Cross-reactivity with other polyene antifungals such as amphotericin B is possible, so history of reactions to related medications should be communicated to the veterinarian.

Natamycin should be used with caution in horses with severely compromised corneal integrity, including those with deep stromal ulceration or descemetocele formation. While the medication itself is not directly harmful to compromised corneas, these severe conditions often require more aggressive intervention, potentially including surgical management, and reliance on topical therapy alone may be inadequate. In such cases, natamycin may be part of a multimodal approach but should not delay necessary surgical intervention.

The safety of natamycin has not been extensively studied in pregnant or lactating mares, though systemic absorption from topical ocular use is minimal. Veterinarians generally consider the medication acceptable for use in breeding animals when the benefit of treating a sight-threatening fungal infection outweighs theoretical risks. However, owners of pregnant mares should discuss any concerns with their veterinarian, who can assess the individual risk-benefit ratio.

Natamycin is not effective against bacterial infections, and its use in purely bacterial keratitis would be inappropriate and potentially harmful by delaying effective antibacterial treatment. Accurate diagnosis through cytology, culture, or both is essential before committing to antifungal therapy. Concurrent bacterial and fungal infections do occur, particularly in chronic or complicated corneal ulcers, and such cases typically require combination therapy with both antibacterial and antifungal medications.

Horses with known deep fungal infections extending beyond the cornea into the anterior chamber or other intraocular structures may not achieve adequate drug concentrations with topical natamycin alone due to limited penetration. While topical therapy remains valuable as part of treatment, systemic antifungal medications and potentially surgical intervention are typically required for these serious infections.

Drug interactions with topically applied natamycin are limited due to minimal systemic absorption. However, when multiple ophthalmic medications are prescribed concurrently, as is common in treating complicated fungal keratitis, proper timing and sequencing of administration becomes important to ensure optimal efficacy of each medication and adequate contact time with the ocular surface.

When natamycin is used alongside other topical ophthalmic medications such as antibiotics, anti-inflammatory agents, or mydriatics, a minimum interval of five to ten minutes should be maintained between different medications. This spacing allows each drug adequate time for absorption or surface activity before being diluted or washed away by the next medication. The order of administration may be specified by the veterinarian based on the specific medications involved and treatment priorities.

Corticosteroid ophthalmic preparations are generally avoided or used with extreme caution during active fungal keratitis treatment. Corticosteroids suppress local immune responses that help contain fungal infections and can dramatically worsen keratomycosis. If anti-inflammatory therapy is deemed necessary for managing concurrent conditions or reducing destructive inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) are typically preferred over corticosteroids, and their use requires careful veterinary oversight.

Natamycin may be used in combination with other antifungal medications for severe or refractory fungal keratitis. Common combinations include natamycin with topical voriconazole or miconazole, or natamycin with systemic antifungals such as oral fluconazole or itraconazole. These combinations may provide synergistic or additive antifungal activity and are particularly valuable for deep stromal infections or those caused by less susceptible organisms. The treating veterinarian determines appropriate combination protocols based on culture results and clinical response.

Atropine ophthalmic solution is frequently prescribed alongside natamycin for fungal keratitis to manage painful ciliary spasm and prevent synechiae formation. This combination is safe and standard practice. Similarly, concurrent use of topical antibiotics to prevent secondary bacterial infection of ulcerated corneas is common and appropriate. Serum or plasma eye drops, used to provide growth factors supporting corneal healing, are compatible with natamycin therapy and often used concurrently in comprehensive treatment protocols.

Treatment of fungal keratitis requires close monitoring by a veterinarian experienced in equine ophthalmology. Response to therapy should be evaluated regularly, typically every few days during the initial acute phase, to assess whether the infection is responding appropriately. Clinical improvement is often gradual, and owners should understand that visible progress may take one to two weeks to become apparent. Worsening despite treatment warrants immediate reassessment and potential modification of the therapeutic approach.

Proper diagnostic evaluation before initiating natamycin therapy is strongly recommended whenever possible. Corneal cytology and culture help confirm fungal involvement and identify the specific organism, guiding treatment decisions and providing prognostic information. While empirical antifungal therapy may be initiated in high-risk situations, definitive diagnosis improves treatment outcomes and allows for targeted therapy if initial treatment proves inadequate.

Competition horses receiving natamycin should be aware that while the medication itself may not be specifically listed as a prohibited substance by most regulatory organizations, the underlying condition requiring treatment typically necessitates withdrawal from competition until the eye has healed. Horses with active corneal ulceration are at risk for further injury during athletic activity. Owners should consult with their veterinarian and review current competition rules before competing while any ophthalmic treatment is ongoing.

Handling precautions for natamycin are minimal given its poor systemic absorption, but persons administering the medication should wash hands before and after application. Contact with the dropper tip should be avoided to prevent contamination of the bottle contents. If accidental human ocular exposure occurs, the eye should be rinsed thoroughly with water. Individuals with known sensitivity to antifungal medications should use caution when handling the product.

Storage and handling of the medication bottle is important for maintaining efficacy. The suspension settles over time, and failure to shake adequately before use results in inconsistent dosing with subtherapeutic drug concentrations. Contamination of the bottle can introduce bacteria into an already compromised eye, so strict attention to avoiding contact between the dropper tip and any surface is essential. Any changes in the appearance of the medication, including unusual discoloration or particle formation, should prompt replacement of the bottle.

Natamycin ophthalmic suspension should be stored at controlled room temperature, typically between 36°F and 77°F (2°C to 25°C), and protected from light and freezing. The medication should not be refrigerated unless specifically directed, as temperature extremes can affect the stability of the suspension and potentially reduce efficacy. In barn or stable environments, finding an appropriate storage location away from temperature extremes and direct sunlight is important.

The bottle should be kept tightly closed when not in use to prevent contamination and evaporation. Before each use, the bottle must be shaken vigorously for at least one minute to ensure uniform suspension of the active ingredient. The medication has a tendency to settle, and inadequate mixing results in variable drug concentrations that may compromise treatment efficacy. Visual inspection should confirm a uniform, milky white appearance after shaking.

Once opened, natamycin ophthalmic suspension typically remains stable for the duration indicated on the product labeling, usually around four weeks, though this may vary by manufacturer. The expiration date on unopened bottles should be observed, and expired medication should not be used. Proper disposal of unused or expired medication should follow local guidelines for pharmaceutical waste, which may include returning to a veterinary clinic or pharmacy for appropriate disposal rather than discarding in household trash or flushing.

Fungal keratitis can affect horses of any breed, though certain factors may influence susceptibility and treatment considerations across different breed types. Draft horses and other large breeds present practical challenges for frequent medication administration due to their height, potentially requiring elevated platforms or alternative restraint approaches. Their larger eye size does not typically necessitate dose adjustment for topical medications, as standard drop volumes are appropriate regardless of breed.

Light horse breeds commonly used for performance activities may face particular challenges due to the intensive treatment schedules required for fungal keratitis. The demanding initial dosing frequency of every one to two hours conflicts with competition and training schedules, and affected horses typically require rest from work until the infection resolves. Performance horse owners should plan for an extended recovery period and discuss return-to-work timelines with their veterinarian.

Ponies and miniature horses may be easier to restrain for medication administration but can present challenges in visualizing the eye and accurately delivering drops to small palpebral fissures. These smaller equines may require additional patience and technique refinement to ensure medication reaches the intended target. Their smaller overall size does not change the topical dose administered.

Appaloosas deserve special mention in discussions of equine ophthalmic medications due to their predisposition to equine recurrent uveitis. While uveitis is a distinct condition from fungal keratitis, Appaloosas with chronic ocular inflammation may have compromised ocular surface defenses that increase susceptibility to opportunistic infections including fungal keratitis. Additionally, the treatments for uveitis sometimes include topical corticosteroids, which must be used with extreme caution if any corneal ulceration or fungal infection is present or suspected. Appaloosa owners should be particularly vigilant about any signs of corneal disease and seek prompt veterinary evaluation for ocular abnormalities.

Several alternative antifungal medications may be used for equine fungal keratitis when natamycin is unavailable, ineffective, or poorly tolerated. Voriconazole, available as a compounded ophthalmic solution, provides excellent broad-spectrum antifungal activity and superior corneal penetration compared to natamycin. This azole antifungal is often preferred for deep stromal infections or those caused by organisms less susceptible to natamycin, though it typically requires compounding pharmacy preparation.

Miconazole, another azole antifungal, may be formulated as an ophthalmic solution for treating equine fungal keratitis. While not commercially available as an ophthalmic preparation, compounded formulations can be prepared for cases where alternative antifungal therapy is needed. Silver sulfadiazine ophthalmic preparations have also been used for their antifungal properties, though these are less commonly employed as primary therapy.

For severe or systemic fungal infections affecting the eye, oral antifungal medications may be prescribed alongside topical therapy. Fluconazole and itraconazole are the most commonly used systemic antifungals in horses, selected based on the specific fungal organism and its susceptibility profile. These systemic medications achieve intraocular drug concentrations that support treatment of deep infections where topical penetration is limited. The decision to add systemic antifungal therapy is made by the veterinarian based on infection severity and location. Owners should never substitute one antifungal medication for another without veterinary guidance, as different agents have distinct spectrums of activity and inappropriate substitution may result in treatment failure.